Stocks
Single names, sectors, valuations and the trades behind the tape, explained in plain language.
NZME buys Stuff's Petone print gear to cut costs
NZME is buying print equipment from rival Stuff's Petone site to run its papers more efficiently. The NZ$15 million investment is expected t
WiseTech flags temporary ASX rule breach over new chair's dual role
WiseTech Global has told the ASX it is temporarily breaching a listing rule because its new chair, Raelene Murphy, is also leading the audit
Kirin to buy Jamieson Wellness for C$2.5 billion in cash deal
Kirin Holdings will buy Jamieson Wellness for C$2.5 billion, paying C$45.75 per share in cash. The deal, a 27% premium to the stock's recent
Zillow's postpaid shift may dent near-term revenue, RBC warns
RBC Capital Markets warns Zillow's quicker shift to a postpaid Preferred model could weigh on near-term revenue and margins. The model delay
RBC Holds Angi Rating at Sector Perform, Cuts Forecasts After Soft Q2
RBC maintained its sector perform rating and $5 price target on Angi after the company's Q2 results came in softer than expected. The bank c
Air Products raises outlook as chip demand fuels $3B backlog
Air Products beat fiscal Q3 expectations and raised its outlook, with RBC pointing to a $3B+ backlog, $2.4B tied to electronics. Chip demand
Alkami launches sale process after Jana builds 5.1% stake
Alkami Technology has kicked off a sale process, with advisers contacting private equity firms after activist Jana Partners built a 5.1% sta
Morgan Stanley raises Axon price target to $640 on strong bookings
Morgan Stanley raised its price target on Axon to $640 from $600, pointing to $15.1 billion in contracted bookings and stronger revenue grow
Onterris downgraded by BofA as 2026 outlook weakens, strategic review begins
Bank of America downgraded Onterris to underperform and cut its price target to $18 from $31 after the company lowered 2026 EBITDA guidance
CDW's Q2 beat overshadowed by margin worries, Morgan Stanley says
CDW delivered a strong second quarter, but investors zeroed in on softer gross margins. Morgan Stanley argues the market is overreacting, no
Berenberg lifts Next target as international online sales surge
Berenberg lifted its price target on Next to £187 after the retailer's Q2 full-price sales rose 9.2%. The growth was powered by a 36.9% surg
Tarsus to buy Alkeus for up to $800M, adding Stargardt disease drug
Tarsus Pharmaceuticals is buying Alkeus for up to $800 million, adding a late-stage treatment for Stargardt disease, a rare inherited retina